Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02714387
Other study ID # RC12_0207 cohorte fiche 1
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 2013
Est. completion date January 2050

Study information

Verified date September 2022
Source Nantes University Hospital
Contact Karim Asehnoune, PhD, MD
Phone 02 40 08 73 80
Email karim.asehnoune@chu-nantes.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this observational epidemiological study is to investigate the management and the complications associated with Non Traumatic Neuro-Vascular Diseases. Data will be analysed to answer pre-defined scientific projects and to improve management of these conditions.


Description:

Anonymous data will be collected by study coordinators in a secured e-database. Cross audit will be performed to check data.


Recruitment information / eligibility

Status Recruiting
Enrollment 5000
Est. completion date January 2050
Est. primary completion date January 2050
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: - Non Traumatic Neuro-Vascular Diseases Exclusion Criteria: - Consent withdrawal

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Collection of medical data
A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.

Locations

Country Name City State
France Angers University Hospital Angers
France CHU de Brest La Cavale Blanche Brest
France Nantes University Hospital Nantes
France Poitiers University Hospital Poitiers
France Rennes University Hospital Rennes
France Tours University Hospital Tours

Sponsors (1)

Lead Sponsor Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Death in ICU (up to 180 days)
Primary in ICU stay complications Hospital acquired infections (epidemiology, risk factors, antibiotic susceptibility of pathogens), Organ failures (incidence, risks factors), Bleeding, Hemorrhage Intra-Cranial Hypertension, Brain Ischemia, Mechanical ventilation weaning, Extubation failure Within the first 28 days after ICU admission date
Secondary Duration in mechanical ventilation in ICU (up to 90 days)
Secondary ICU length of stay in ICU (up to 90 days)